Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Assets Average (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Assets Average for 11 consecutive years, with $270.3 million as the latest value for Q4 2025.

  • Quarterly Assets Average fell 34.0% to $270.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $270.3 million through Dec 2025, down 34.0% year-over-year, with the annual reading at $322.7 million for FY2025, 13.3% down from the prior year.
  • Assets Average hit $270.3 million in Q4 2025 for Voyager Therapeutics, down from $305.2 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $452.9 million in Q2 2024 to a low of $170.9 million in Q4 2022.
  • Historically, Assets Average has averaged $291.1 million across 5 years, with a median of $287.7 million in 2023.
  • Biggest five-year swings in Assets Average: skyrocketed 88.96% in 2023 and later plummeted 34.0% in 2025.
  • Year by year, Assets Average stood at $189.3 million in 2021, then fell by 9.72% to $170.9 million in 2022, then soared by 88.96% to $323.0 million in 2023, then increased by 26.81% to $409.5 million in 2024, then crashed by 34.0% to $270.3 million in 2025.
  • Business Quant data shows Assets Average for VYGR at $270.3 million in Q4 2025, $305.2 million in Q3 2025, and $337.7 million in Q2 2025.